Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer
Purpose: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therape...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/1/147 |
| _version_ | 1797542363327889408 |
|---|---|
| author | Leticia Díaz-Beltrán Carmen González-Olmedo Natalia Luque-Caro Caridad Díaz Ariadna Martín-Blázquez Mónica Fernández-Navarro Ana Laura Ortega-Granados Fernando Gálvez-Montosa Francisca Vicente José Pérez del Palacio Pedro Sánchez-Rovira |
| author_facet | Leticia Díaz-Beltrán Carmen González-Olmedo Natalia Luque-Caro Caridad Díaz Ariadna Martín-Blázquez Mónica Fernández-Navarro Ana Laura Ortega-Granados Fernando Gálvez-Montosa Francisca Vicente José Pérez del Palacio Pedro Sánchez-Rovira |
| author_sort | Leticia Díaz-Beltrán |
| collection | DOAJ |
| description | Purpose: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. Methods: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. Results: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected <i>p</i>-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. Conclusion: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies. |
| first_indexed | 2024-03-10T13:29:32Z |
| format | Article |
| id | doaj.art-ede90584cb8a4f619de82ab399a57401 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T13:29:32Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ede90584cb8a4f619de82ab399a574012023-11-21T08:21:08ZengMDPI AGCancers2072-66942021-01-0113114710.3390/cancers13010147Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast CancerLeticia Díaz-Beltrán0Carmen González-Olmedo1Natalia Luque-Caro2Caridad Díaz3Ariadna Martín-Blázquez4Mónica Fernández-Navarro5Ana Laura Ortega-Granados6Fernando Gálvez-Montosa7Francisca Vicente8José Pérez del Palacio9Pedro Sánchez-Rovira10Medical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, 18016 Granada, Andalucía, SpainFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, 18016 Granada, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, 18016 Granada, Andalucía, SpainFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, 18016 Granada, Andalucía, SpainMedical Oncology Unit, University Hospital of Jaén, 23007 Jaén, Andalucía, SpainPurpose: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. Methods: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. Results: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected <i>p</i>-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. Conclusion: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.https://www.mdpi.com/2072-6694/13/1/147human plasma metabolomicsbreast cancermolecular subtypesmetabolic profilingpersonalized medicine |
| spellingShingle | Leticia Díaz-Beltrán Carmen González-Olmedo Natalia Luque-Caro Caridad Díaz Ariadna Martín-Blázquez Mónica Fernández-Navarro Ana Laura Ortega-Granados Fernando Gálvez-Montosa Francisca Vicente José Pérez del Palacio Pedro Sánchez-Rovira Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer Cancers human plasma metabolomics breast cancer molecular subtypes metabolic profiling personalized medicine |
| title | Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer |
| title_full | Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer |
| title_fullStr | Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer |
| title_full_unstemmed | Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer |
| title_short | Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer |
| title_sort | human plasma metabolomics for biomarker discovery targeting the molecular subtypes in breast cancer |
| topic | human plasma metabolomics breast cancer molecular subtypes metabolic profiling personalized medicine |
| url | https://www.mdpi.com/2072-6694/13/1/147 |
| work_keys_str_mv | AT leticiadiazbeltran humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT carmengonzalezolmedo humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT natalialuquecaro humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT caridaddiaz humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT ariadnamartinblazquez humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT monicafernandeznavarro humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT analauraortegagranados humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT fernandogalvezmontosa humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT franciscavicente humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT joseperezdelpalacio humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer AT pedrosanchezrovira humanplasmametabolomicsforbiomarkerdiscoverytargetingthemolecularsubtypesinbreastcancer |